See more : AMTE Power plc (AMTE.L) Income Statement Analysis – Financial Results
Complete financial analysis of Acceleron Pharma Inc. (XLRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acceleron Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Integrated Cyber Solutions Inc (ICS.CN) Income Statement Analysis – Financial Results
- Companhia Energética do Ceará – Coelce (COCE5.SA) Income Statement Analysis – Financial Results
- Rush Enterprises, Inc. (RUSHB) Income Statement Analysis – Financial Results
- Fuji Corporation (6134.T) Income Statement Analysis – Financial Results
- Al-Modawat Specialized Medical Co. (9594.SR) Income Statement Analysis – Financial Results
Acceleron Pharma Inc. (XLRN)
About Acceleron Pharma Inc.
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 173.92M | 153.95M | 103.90M | 89.73M | 68.58M | 58.40M | 50.90M | 36.05M | 35.32M | 32.71M |
| General & Administrative | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Other Expenses | 85.91M | 56.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 40.86M |
| Cost & Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 42.36M |
| Interest Income | 2.87M | 10.71M | 5.57M | 2.55M | 1.85M | 512.00K | 83.00K | 39.00K | 91.00K | 17.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 922.00K | 2.09M | 1.53M | 1.82M |
| Depreciation & Amortization | 3.85M | 3.94M | 3.75M | 2.83M | 1.68M | 1.18M | 1.12M | 915.00K | 1.29M | 3.13M |
| EBITDA | -162.16M | -120.98M | -115.15M | -105.60M | -55.31M | -62.72M | -49.22M | -18.89M | -29.76M | 41.22M |
| EBITDA Ratio | -175.27% | -163.50% | -823.04% | -783.30% | -199.18% | -346.57% | -336.38% | -33.01% | -195.10% | 50.95% |
| Operating Income | -167.31M | -136.45M | -124.41M | -109.98M | -66.11M | -60.88M | -50.46M | 6.95M | -28.89M | 38.56M |
| Operating Income Ratio | -180.83% | -184.40% | -889.24% | -815.84% | -238.04% | -336.40% | -344.89% | 12.15% | -189.39% | 47.65% |
| Total Other Income/Expenses | 1.30M | 11.53M | 5.52M | 1.56M | 9.12M | -3.02M | -795.00K | -28.85M | -3.69M | -2.29M |
| Income Before Tax | -166.01M | -124.92M | -118.90M | -108.42M | -56.99M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Income Before Tax Ratio | -179.42% | -168.83% | -849.82% | -804.26% | -205.21% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| Income Tax Expense | 21.00K | -62.00K | -27.00K | 32.00K | 24.00K | -3.02M | 127.00K | -26.76M | -2.16M | -468.00K |
| Net Income | -166.03M | -124.86M | -118.87M | -108.45M | -57.01M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Net Income Ratio | -179.45% | -168.74% | -849.62% | -804.50% | -205.30% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| EPS | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.73 |
| EPS Diluted | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.58 |
| Weighted Avg Shares Out | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 20.95M |
| Weighted Avg Shares Out (Dil) | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 22.97M |
Why Acceleron Pharma Stock Jumped This Week
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q2 2021 Results - Earnings Call Transcript
Acceleron Pharma (XLRN) Reports Q2 Loss, Misses Revenue Estimates
Acceleron Pharma: Q2 Earnings Insights
Acceleron Reports Second Quarter 2021 Financial Results
Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales
Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021
Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021
BioNTech, CyberArk, Vertex Pharma and More Monday Afternoon Analyst Calls
Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021
Source: https://incomestatements.info
Category: Stock Reports